Evidence map›Paper›PMID 41419769›Full record

ArticleNature communications2025

Author Correction: Microbiota-reprogrammed phosphatidylcholine inactivates cytotoxic CD8 T cells through UFMylation via exosomal SerpinB9 in multiple myeloma.

Wei Yan, Xue Shi, Yun Zhao, Xiaoyu Liu, Xueming Jia, Le Gao, Jiahe Yuan, Aijun Liao, Hiroshi Yasui, Xiaobin Wang and 3 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Wei Yan *Department of Hematology, Shengjing Hospital, China Medical University, Shenyang, China.
Xue Shi *Department of Hematology, Shengjing Hospital, China Medical University, Shenyang, China.
Yun Zhao *Department of Radiology, Shengjing Hospital, China Medical University, Shenyang, China.
Xiaoyu LiuDepartment of Hematology, Shengjing Hospital, China Medical University, Shenyang, China.
Xueming JiaDepartment of Hematology, Shengjing Hospital, China Medical University, Shenyang, China.
Le GaoDepartment of Hematology, Shengjing Hospital, China Medical University, Shenyang, China.
Jiahe YuanDepartment of Hematology, Shengjing Hospital, China Medical University, Shenyang, China.
Aijun LiaoDepartment of Hematology, Shengjing Hospital, China Medical University, Shenyang, China.
Hiroshi YasuiDepartment of Hematology and Oncology, St. Marianna University School of Medicine, Kawasaki, Japan.ORCID http://orcid.org/0000-0003-0905-6855
Xiaobin WangCenter for Reproductive Medicine, Shengjing Hospital, China Medical University, Shenyang, China. wangxb@sj-hospital.org.
Xiaotian WangDepartment of Urology, Shengjing Hospital, China Medical University, Shenyang, China. 18940252998@163.com.
Rui ZhangDepartment of Hematology, The First Affiliated Hospital, China Medical University, Shenyang, China. hemozerro2008@hotmail.com.
Huihan WangDepartment of Hematology, Shengjing Hospital, China Medical University, Shenyang, China. wanghh@sj-hospital.org.ORCID http://orcid.org/0000-0003-1141-5263

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41419769
PMCPMC12717032

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.